Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects

NCT03646123 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03646123
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03646123 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
January 28, 2019
Completion date
August 23, 2024
Enrollment
255 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma